Refractory Mycosis Fungoides/Sezary Syndrome Completed Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Mycosis fungoides/Sezary syndrome refractory / Refractory Mycosis Fungoides and Sezary Syndrome / Cutaneous T-cell lymphoma refractory

IndicationStatusPhase
DBCOND0126278 (Refractory Mycosis Fungoides/Sezary Syndrome)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03063632Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S├ęzary Syndrome and Advanced Synovial SarcomaTreatment
NCT02243579Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary SyndromeTreatment